培美曲塞治疗老年晚期非小细胞肺癌的临床观察  

Clincal obsevation of pemetrexed in treating elder non-small cell lung cancer

作　　者：阳月新[1] 李鹏飞[1] 邱波[1] 付挺 张淑芳[1] 

机构地区：[1]湖南省株洲市一医院肿瘤科,湖南株洲412000

出　　处：《中国医学工程》2009年第1期57-59,共3页China Medical Engineering

摘　　要：目的评价培美曲塞(pemetrexed,PEM)治疗老年不可手术的局部晚期非小细胞肺癌(NSCLC)的有效性和安全性。方法45例老年不可手术的Ⅲa和Ⅲb期NSCLC患者接受PEM单药或与顺铂联合化疗,单药培美曲塞:500mg/m2,静脉滴注第1天,静脉滴注大于10min;每3周重复。顺铂25mg/m2,静脉推注,第1～3天,治疗前后适当进行水化;每3周重复。用培美曲塞前1周口服叶酸400μg,1次/d,连服到培美曲塞结束后21d;用培美曲塞前1周给予VitB121000μg肌注,每9周1次;用培美曲塞前24h口服地塞米松4mg,2次/d,连服3d。结果全组45例,完全缓解(CR)1例,部分缓解(PR)23例,稳定(SD)16例,进展(PD)5例,有效率RR(CR+PR)53%,临床收益率CBR(CR+PR+SD)89%,疾病进展时间(TTP)13.6周。主要毒副反应为骨髓抑制,胃肠道反应,均未达到Ⅳ度,均可耐受,经对症治疗不影响化疗进行。结论以培美曲塞为主的化疗治疗老年晚期非小细胞肺癌具有较好疗效,且毒性反应轻,耐受性好,但临床病例较少,仍需进一步大样本研究。[Objective] To evaluate the clinical efficacy and safety of pemetrexed in treating old patients with non-small Cell lung cancer. [Methods] 45 senior patients with NSCLC diagfiosed by histology or cytology were enrolled into the study. 14 patients were treated by pemetrexed alone, 31 patients by pemetrexed plus eisplatin. [Resuits] The total response rate was 53%.The median TIP was 13.6 weeks. The main toxieities were hematological toxieities, nausea and vomiting, and diarrhoea. [Conelusion] The regimen of pemetrexed is effective, safe and welltolerable in the treatment of old patients with NSCLC.

关 键 词：非小细胞肺癌 培美曲塞 化疗 老年人 

分 类 号：R734.2[医药卫生—肿瘤]